Latest Europe News

Middle Island Resources has completed its Phase 2 drilling at the Bobija polymetallic project in Serbia, reinforcing continuity of gold-silver-base metal mineralisation. Extensive soil sampling across Tisovik, Priboj, and Ober projects has identified multiple promising targets, with RC drilling planned pending land access approvals.

Argenica Therapeutics is progressing its ARG-007 drug toward a targeted Phase 2b trial for acute ischaemic stroke, leveraging AI for patient selection and securing key regulatory approvals, while maintaining a solid cash position of $8 million.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Osmond Resources has released final assays from its Phase 1 drilling at the Orión EU Critical Minerals Project in Spain, revealing significant enrichment of titanium, zirconium, and rare earth elements over a 10km strike. The discovery of a new basal mineralised seam adds to the project's scale, with Phase 2 drilling imminent and a Scoping Study targeted for late 2026.

OncoSil Medical reported a 60% year-on-year increase in dose sales in Q3 FY26, boosted by expanding treatment centres and advancing clinical trials, while cost-cutting and a new manufacturing facility aim to underpin growth.

PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.

Orthocell’s latest Remplir™ Real World Evidence study reveals an 89.7% treatment success rate across 78 nerve repair procedures, reinforcing its clinical strength and fueling US and European market growth plans.

Way2VAT reported a 95% surge in Q1 FY26 revenue to $2.05 million, driven by its RBC acquisition and expanding client base, while preparing to launch an e-invoicing platform integrating AI-powered APAI technology.

Imricor Medical Systems advanced FDA clearances and expanded clinical trials in Q1 CY26, positioning for commercial growth despite higher operating cash outflows.

ECS Botanics reports a third straight quarter of positive operating cash flow, driven by strong B2C growth and strategic international shipments to Germany and New Zealand.

PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.

AML3D has maintained a steady $2.2 million quarterly revenue run rate and secured $12.5 million in new orders during 3Q26, pushing its total orders for FY2026 to $29 million. The company is aggressively expanding its US manufacturing footprint and making initial inroads into UK and European defence markets.